Adult glucocorticoid receptor blockade reverses the programming effects of brief and repeated social isolation stress during adolescence in rats
Journal of Neuroendocrinology · 2026-11 · 38 (11)
DOI: 10.1111/jne.70307 ↗Abstract
Abstract Social isolation during adolescence represents a significant risk factor for the development of psychopathologies later in life. While numerous preclinical studies have modeled psychopathologies using prolonged and continuous social isolation stress (SIS), the detrimental effects of shorter periods of SIS, particularly during critical developmental windows, are less explored. Here, we characterized a paradigm of brief and repeated SIS (bSIS) during early‐adolescence, a stress‐sensitive period, and examined its behavioral and neurobiological consequences in adulthood. Male rats were subjected to bSIS (2 h/day, postnatal days, [PND] 28–34), and effects on emotionality and memory function were later assessed using several behavioral tests. We found that bSIS induced long‐lasting alterations selectively in the emotional domain (e.g., increased anxious‐like behavior in the elevated plus maze test, and enhanced acoustic startle response). In a separate cohort, we investigated the brain regions bSIS‐activated and identified cingulate cortex area 1 (Cg1) as a potential key region mediating its effects. Given previous evidence that the glucocorticoid receptor (GR) antagonist mifepristone can reverse stress‐induced effects, we tested its efficacy in adulthood in our model (PND 83, 85, and 87) and found that it remarkably normalized the behavioral bSIS‐induced alterations. To explore the underlying molecular mechanisms, we performed bulk RNA sequencing in the Cg1, but no significant transcriptomic changes were detected, likely due to the transient nature of bSIS‐induced effects. Overall, our findings demonstrate that bSIS during early‐adolescence produces programming alterations, and that late GR antagonism effectively reverses these outcomes, highlighting a potential pharmacological target for stress‐related disorders.
EUVIMED